Halberd Corporation (OTCMKTS:HALB) Meets with CDC Leads to Expanded Testing of Antibiotic Resistant Pathogens

Halberd Corporation (OTCMKTS:HALB) has made rapid strides with its Centers for Disease Control and Prevention (CDC) testing work for antibiotic-resistant antigens over the course of the past week. Not too long ago on March 29, the company’s representatives met with five representatives from the CDC with regard to the progress done so far.

The company came up with an update from the meeting back on April 3 and noted that the CDC team was impressed with the sort of work that had been accomplished so far in the testing work in collaboration with Youngstown State University. The presentation was led by Dr. Chester Cooper, who is a professor at the Department of Chemical and Biological Sciences at Youngstown State University.

Halberd announced that during the course of the meeting, the team from CDC noted the effective testing that had been accomplished by Halberd using its own technology and methods.

More importantly, the team also committed to sending even more antigen samples, which are dangerous and antibiotic-resistant, to Halberd, in light of the stellar work accomplished by the company. The two parties would also have a follow-up meeting after the testing work on these new antigens is completed.